Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | SIRT2 | Q8IXJ6 | 2/20 | 0.51 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.49 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL62795 | 0.94 | HPGD (0.56) | HPGDHTTSIRT2SIRT1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL7313025 | 0.93 | HPGD (0.55) | HPGDHTTSIRT2SIRT1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9742136 | 0.93 | HPGD (0.55) | HPGDHTTSIRT2SIRT1ALDH1A1 | |
| Bromide SCHEMBL15106751 | 0.93 | HPGD (0.55) | HPGDHTTSIRT2SIRT1ALDH1A1 | |
| SCHEMBL3898465 | 0.87 | HPGD (0.61) | HPGDHTTSIRT2SIRT1ALDH1A1 | |
| SCHEMBL28242074 | 0.87 | HPGD (0.61) | HPGDHTTSIRT2SIRT1ALDH1A1 | |
| SCHEMBL3900474 | 0.86 | SIRT2 (0.60) | HPGDHTTSIRT2SIRT1ALDH1A1 | |
| SCHEMBL20187714 | 0.86 | HPGD (0.59) | HPGDHTTSIRT2SIRT1ALDH1A1 | |
| SCHEMBL20188098 | 0.84 | HPGD (0.65) | HPGDHTTALDH1A1TSHRMEN1 | |
| SCHEMBL22015905 | 0.84 | HPGD (0.65) | HPGDHTTALDH1A1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113677341-B | Bicyclic pyridine compositions and methods for their use in cancer treatment | 南卡罗莱纳大学 | 2024-07-05 | — | — | CN | disclosed |
| WO-2023081452-A1 | SMALL-MOLECULE DEGRADERS OF CDK8 AND CDK19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2023-05-11 | — | — | WO | disclosed |
| US-11572369-B2 | Bicyclic pyridine compositions and methods of using the same for cancer therapy | UNIVERSITY OF SOUTH CAROLINA (US) | 2023-02-07 | — | — | US | disclosed |
| US-11572369-B2 | Bicyclic pyridine compositions and methods of using the same for cancer therapy | UNIVERSITY OF SOUTH CAROLINA (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220135583-A1 | BICYCLIC PYRIDINE COMPOSITIONS AND METHODS OF USING THE SAME FOR CANCER THERAPY | UNIVERSITY OF SOUTH CAROLINA | 2022-05-05 | — | — | US | disclosed |
| US-20220135583-A1 | BICYCLIC PYRIDINE COMPOSITIONS AND METHODS OF USING THE SAME FOR CANCER THERAPY | UNIVERSITY OF SOUTH CAROLINA | 2022-05-05 | — | — | US | disclosed |
| EP-3917523-A1 | BICYCLIC PYRIDINE COMPOSITIONS AND METHODS OF USING THE SAME FOR CANCER THERAPY | University of South Carolina (US) | 2021-12-08 | — | — | EP | disclosed |
| CN-113677341-A | Bicyclic pyridine compositions and methods of use for cancer treatment | 南卡罗莱纳大学 | 2021-11-19 | — | — | CN | disclosed |
| WO-2020160537-A1 | BICYCLIC PYRIDINE COMPOSITIONS AND METHODS OF USING THE SAME FOR CANCER THERAPY | UNIVERSITY OF SOUTH CAROLINA (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160537-A1 | BICYCLIC PYRIDINE COMPOSITIONS AND METHODS OF USING THE SAME FOR CANCER THERAPY | UNIVERSITY OF SOUTH CAROLINA (US) | 2020-08-06 | — | — | WO | disclosed |
| US-20120129844-A1 | N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF | ASTRAZENECA AB | 2012-05-24 | — | — | US | disclosed |
| US-8129391-B2 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2012-03-06 | — | — | US | disclosed |
| EP-2125748-B1 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-20100273811-A1 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof | ASTRAZENECA AB | 2010-10-28 | — | — | US | disclosed |
| US-7737149-B2 | N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof | ASTRAZENECA AB (SE) | 2010-06-15 | — | — | US | disclosed |
| EP-2125748-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | AstraZeneca AB (SE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008075068-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-6451800-B1 | Phenylpiperazine derivatives as integrin αvβ3 antagonists | MEIJI SEIKA KAISHA, LTD. (JP) | 2002-09-17 | — | — | US | disclosed |
| EP-1057818-A1 | PHENYLPIPERAZINE DERIVATIVES AS INTEGRIN ALPHAvBETA3 ANTAGONISTS | MEIJI SEIKA KAISHA LTD. (JP) | 2000-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273811-A1 | N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof | PKD1, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HPGD 1000/4885HTT 4466/4885SIRT2 975/4885 |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | HDAC1, HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HPGD 185/4885HTT 2923/4885SIRT2 64/4885 |
| US-20120129844-A1 | N-[5-[2-(3,5-DIMETHOXYPHENYL)ETHYL]-1H-PYRAZOL-3-YL]-4-(3,4-DIMETHYLPIPERAZIN-1-YL)BENZAMIDE AND SALTS THEREOF | PKD1, SDHA, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HPGD 1000/4885HTT 4466/4885SIRT2 975/4885 |
| US-20220135583-A1 | BICYCLIC PYRIDINE COMPOSITIONS AND METHODS OF USING THE SAME FOR CANCER THERAPY | DPYD, TK2, TYMP | HPGD 160/4885HTT 3887/4885SIRT2 285/4885 |
| US-11572369-B2 | Bicyclic pyridine compositions and methods of using the same for cancer therapy | DPYD, TK2, TYMP | HPGD 160/4885HTT 3887/4885SIRT2 285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.